Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2023-06-26 Regulatory Filings
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-06-26 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 23, 2023, by Akero Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the Annual Meeting held on June 23, 2023. It details the voting results on director elections, ratification of the auditor, and advisory vote on executive compensation. The document specifically reports the official results of shareholder votes. There is no indication that this is a full annual report, earnings release, or other financial report. The focus on voting results aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 4811 characters, which is sufficient to include detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2023-06-26 English
4
Director's Dealing
2023-06-24 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-22 English
4
Director's Dealing
2023-06-21 English
4
Director's Dealing
2023-06-21 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.